Showing 73 - 84 of 115 results for "05751"
Products 1 to 12 of 25 total
- ReferenceKaur G et al. (JUL 2013) Journal of Clinical Neuroscience 20 7 1014--1018
G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells
Glioblastoma multiforme (GBM) is a grade IV malignant brain tumor with high mortality and has been well known to involve many molecular pathways, including G-protein coupled receptor (GPCR)-mediated signaling (such as epithelial growth factor receptor [EGFR] and platelet derived growth factor receptor [PDGFR]). G protein-coupled receptor kinases (GRK) directly regulate GPCR activity by phosphorylating activated agonist-bound receptors to desensitize signaling and internalize receptors through beta-arrestins. Recent studies in various cancers, including prostate and breast cancer, have highlighted the role of change in GRK expression to oncogenesis and tumor proliferation. In this study, we evaluated the expression of GRK5 in grade II to grade IV glioma specimens using immunohistochemistry and found that GRK5 expression levels are highly correlated with aggressiveness of glioma. We used culture conditions to selectively promote the growth of either glioblastoma cells with stem cell markers (GSC) or differentiated glioblastoma cells (DGC) from fresh GBM specimens. GSC are known to be highly invasive and mobile, and have the capacity to self-renew and are more resistant to chemotherapy and radiation compared to differentiated populations of GBM. We examined the expression of GRK5 in these two sets of culturing conditions for GBM cells and found that GRK5 expression is upregulated in GSC compared to differentiated GBM cells. To better understand the role of GRK5 in GBM-derived stem cells, we created stable GRK5 knockdown and evaluated the proliferation rate. Using an ATP chemiluminescence assay, we show, for the first time, that knocking down the expression of GRK5 decreased the proliferation rate of GSC in contrast to control. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceJi M et al. (SEP 2013) Science Translational Medicine 5 201 201ra119--201ra119
Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy
Surgery is an essential component in the treatment of brain tumors. However, delineating tumor from normal brain remains a major challenge. We describe the use of stimulated Raman scattering (SRS) microscopy for differentiating healthy human and mouse brain tissue from tumor-infiltrated brain based on histoarchitectural and biochemical differences. Unlike traditional histopathology, SRS is a label-free technique that can be rapidly performed in situ. SRS microscopy was able to differentiate tumor from nonneoplastic tissue in an infiltrative human glioblastoma xenograft mouse model based on their different Raman spectra. We further demonstrated a correlation between SRS and hematoxylin and eosin microscopy for detection of glioma infiltration (κ = 0.98). Finally, we applied SRS microscopy in vivo in mice during surgery to reveal tumor margins that were undetectable under standard operative conditions. By providing rapid intraoperative assessment of brain tissue, SRS microscopy may ultimately improve the safety and accuracy of surgeries where tumor boundaries are visually indistinct. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceJarzabek MA et al. (DEC 2014) British journal of cancer 111 12 2275--86
Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.
BACKGROUND Glioblastoma (GBM), being a highly vascularised and locally invasive tumour, is an attractive target for anti-angiogenic and anti-invasive therapies. The GBM/endothelial cell response to gossypol/temozolomide (TMZ) treatment was investigated with a particular aim to assess treatment effects on cancer hallmarks. METHODS Cell viability, endothelial tube formation and GBM tumour cell invasion were variously assessed following combined treatment in vitro. The U87MG-luc2 subcutaneous xenograft model was used to investigate therapeutic response in vivo. Viable tumour response to treatment was interrogated using immunohistochemistry. Combined treatment protocols were also tested in primary GBM patient-derived cultures. RESULTS An endothelial/GBM cell viability inhibitory effect, as well as an anti-angiogenic and anti-invasive response, to combined treatment have been demonstrated in vitro. A significantly greater anti-proliferative (P=0.020, P=0.030), anti-angiogenic (P=0.040, P<0.0001) and pro-apoptotic (P=0.0083, P=0.0149) response was observed when combined treatment was compared with single gossypol/TMZ treatment response, respectively. GBM cell line and patient-specific response to gossypol/TMZ treatment was observed. CONCLUSIONS Our results indicate that response to a combined gossypol/TMZ treatment is related to inhibition of tumour-associated angiogenesis, invasion and proliferation and warrants further investigation as a novel targeted GBM treatment strategy. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceAbeysinghe HCS et al. (SEP 2015) Stem cell research & therapy 6 1 186
Pre-differentiation of human neural stem cells into GABAergic neurons prior to transplant results in greater repopulation of the damaged brain and accelerates functional recovery after transient ischemic stroke.
INTRODUCTION Despite attempts to prevent brain injury during the hyperacute phase of stroke, most sufferers end up with significant neuronal loss and functional deficits. The use of cell-based therapies to recover the injured brain offers new hope. In the current study, we employed human neural stem cells (hNSCs) isolated from subventricular zone (SVZ), and directed their differentiation into GABAergic neurons followed by transplantation to ischemic brain. METHODS Pre-differentiated GABAergic neurons, undifferentiated SVZ-hNSCs or media alone were stereotaxically transplanted into the rat brain (n=7/group) 7 days after endothelin-1 induced stroke. Neurological outcome was assessed by neurological deficit scores and the cylinder test. Transplanted cell survival, cellular phenotype and maturation were assessed using immunohistochemistry and confocal microscopy. RESULTS Behavioral assessments revealed accelerated improvements in motor function 7 days post-transplant in rats treated with pre-differentiated GABAergic cells in comparison to media alone and undifferentiated hNSC treated groups. Histopathology 28 days-post transplant indicated that pre-differentiated cells maintained their GABAergic neuronal phenotype, showed evidence of synaptogenesis and up-regulated expression of both GABA and calcium signaling proteins associated with neurotransmission. Rats treated with pre-differentiated cells also showed increased neurogenic activity within the SVZ at 28 days, suggesting an additional trophic role of these GABAergic cells. In contrast, undifferentiated SVZ-hNSCs predominantly differentiated into GFAP-positive astrocytes and appeared to be incorporated into the glial scar. CONCLUSION Our study is the first to show enhanced exogenous repopulation of a neuronal phenotype after stroke using techniques aimed at GABAergic cell induction prior to delivery that resulted in accelerated and improved functional recovery. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferencePollak J et al. (MAR 2017) PLOS ONE 12 3 e0172884
Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy
Ion channels and transporters have increasingly recognized roles in cancer progression through the regulation of cell proliferation, migration, and death. Glioblastoma stem-like cells (GSCs) are a source of tumor formation and recurrence in glioblastoma multiforme, a highly aggressive brain cancer, suggesting that ion channel expression may be perturbed in this population. However, little is known about the expression and functional relevance of ion channels that may contribute to GSC malignancy. Using RNA sequencing, we assessed the enrichment of ion channels in GSC isolates and non-tumor neural cell types. We identified a unique set of GSC-enriched ion channels using differential expression analysis that is also associated with distinct gene mutation signatures. In support of potential clinical relevance, expression of selected GSC-enriched ion channels evaluated in human glioblastoma databases of The Cancer Genome Atlas and Ivy Glioblastoma Atlas Project correlated with patient survival times. Finally, genetic knockdown as well as pharmacological inhibition of individual or classes of GSC-enriched ion channels constrained growth of GSCs compared to normal neural stem cells. This first-in-kind global examination characterizes ion channels enriched in GSCs and explores their potential clinical relevance to glioblastoma molecular subtypes, gene mutations, survival outcomes, regional tumor expression, and experimental responses to loss-of-function. Together, the data support the potential biological and therapeutic impact of ion channels on GSC malignancy and provide strong rationale for further examination of their mechanistic and therapeutic importance. View PublicationCatalog #: Product Name: 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceBayat Mokhtari R et al. (DEC 2017) BMC Cancer 17 1 156
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
BACKGROUND Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required. METHODS We investigated coordinated targeting of essential homeostatic regulatory factors involved in cancer progression, histone deacetylases (HDACs) and carbonic anhydrases (CAs). RESULTS We evaluated the antitumor potential of the HDAC inhibitor (HDACi), pyridylmethyl-N-4-[(2-aminophenyl)-carbamoyl]-benzyl-carbamate (MS-275) in combination with a pan CA inhibitor, acetazolamide (AZ) on NB SH-SY5Y, SK-N-SH and SK-N-BE(2) cells. The key observation was that the combination AZ + MS-275 significantly inhibited growth, induced cell cycle arrest and apoptosis, and reduced migration capacity of NB cell line SH-SY5Y. In addition, this combination significantly inhibited tumor growth in vivo, in a pre-clinical xenograft model. Evidence was obtained for a marked reduction in tumorigenicity and in the expression of mitotic, proliferative, HIF-1α and CAIX. NB xenografts of SH-SY5Y showed a significant increase in apoptosis. CONCLUSION MS-275 alone at nanomolar concentrations significantly reduced the putative cancer stem cell (CSC) fraction of NB cell lines, SH-SY5Y and SK-N-BE(2), in reference to NT2/D1, a teratocarcinoma cell line, exhibiting a strong stem cell like phenotype in vitro. Whereas stemness genes (OCT4, SOX2 and Nanog) were found to be significantly downregulated after MS-275 treatment, this was further enhanced by AZ co-treatment. The significant reduction in initial tumorigenicity and subsequent abrogation upon serial xenografting suggests potential elimination of the NB CSC fraction. The significant potentiation of MS-275 by AZ is a promising therapeutic approach and one amenable for administration to patients given their current clinical utility. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceMarigil M et al. (JAN 2017) PloS one 12 1 e0170501
Development of a DIPG Orthotopic Model in Mice Using an Implantable Guide-Screw System.
OBJECTIVE In this work we set to develop and to validate a new in vivo frameless orthotopic Diffuse Intrinsic Pontine Glioma (DIPG) model based in the implantation of a guide-screw system. METHODS It consisted of a guide-screw also called bolt, a Hamilton syringe with a 26-gauge needle and an insulin-like 15-gauge needle. The guide screw is 2.6 mm in length and harbors a 0.5 mm central hole which accepts the needle of the Hamilton syringe avoiding a theoretical displacement during insertion. The guide-screw is fixed on the mouse skull according to the coordinates: 1mm right to and 0.8 mm posterior to lambda. To reach the pons the Hamilton syringe is adjusted to a 6.5 mm depth using a cuff that serves as a stopper. This system allows delivering not only cells but also any kind of intratumoral chemotherapy, antibodies or gene/viral therapies. RESULTS The guide-screw was successfully implanted in 10 immunodeficient mice and the animals were inoculated with DIPG human cell lines during the same anesthetic period. All the mice developed severe neurologic symptoms and had a median overall survival of 95 days ranging the time of death from 81 to 116 days. Histopathological analysis confirmed tumor into the pons in all animals confirming the validity of this model. CONCLUSION Here we presented a reproducible and frameless DIPG model that allows for rapid evaluation of tumorigenicity and efficacy of chemotherapeutic or gene therapy products delivered intratumorally to the pons. View PublicationCatalog #: Product Name: 05711 NeuroCult™ SM1 Neuronal Supplement 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05711 Product Name: NeuroCult™ SM1 Neuronal Supplement Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceGundemir S et al. (SEP 2016) Neuro-Oncology now157
The complex role of transglutaminase 2 in glioblastoma proliferation
BACKGROUND Glioblastomas (GBMs) are a heterogeneous group of primary brain tumors. These tumors are resistant to therapeutic interventions and invariably recur after surgical resection. The multifunctional protein transglutaminase 2 (TG2) has been shown to promote cell survival in a number of different tumors. There is also evidence that TG2 may be a pro-survival factor in GBMs. However, the roles that TG2 plays in facilitating GBM survival and proliferation have not yet been clearly delineated . METHODS The functions of TG2 are often cell- and context-specific. Therefore, in this study we examined the ability of TG2 to facilitate GBM proliferation using colony formation assays and 5-ethynyl-2'-deoxyuridine (EdU) incorporation in several different GBM cell lines as well as neurospheres derived from patient tumors representing the 3 major subtypes of GBM tumors (mesenchymal, proneural, and classical) and maintained in the absence of serum. TG2 knockdown or selective TG2 inhibitors were used to modulate TG2 expression and activity. RESULTS We show that TG2 plays differential roles in the proliferative process depending on the cell type. In most, but not all, GBM models TG2 plays a crucial role in the proliferative process, and some but not all TG2 inhibitors were highly effective at reducing proliferation in a large subset of the GBM models. CONCLUSION Our results show that TG2 plays an important-but notoriously context-specific-role in GBM cell biology. Nonetheless, as future studies unravel the genetic fingerprints" that make TG2 inhibitors effective this information could be exploited to develop TG2 inhibitors into personalized GBM therapies. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceHuat T et al. (APR 2015) International Journal of Molecular Sciences 16 5 9693--9718
MicroRNA Expression Profile of Neural Progenitor-Like Cells Derived from Rat Bone Marrow Mesenchymal Stem Cells under the Influence of IGF-1, bFGF and EGF
Insulin-like growth factor 1 (IGF-1) enhances cellular proliferation and reduces apoptosis during the early differentiation of bone marrow derived mesenchymal stem cells (BMSCs) into neural progenitor-like cells (NPCs) in the presence of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). BMSCs were differentiated in three groups of growth factors: (A) EGF + bFGF, (B) EGF + bFGF + IGF-1, and (C) without growth factor. To unravel the molecular mechanisms of the NPCs derivation, microarray analysis using GeneChip miRNA arrays was performed. The profiles were compared among the groups. Annotated microRNA fingerprints (GSE60060) delineated 46 microRNAs temporally up-regulated or down-regulated compared to group C. The expressions of selected microRNAs were validated by real-time PCR. Among the 46 microRNAs, 30 were consistently expressed for minimum of two consecutive time intervals. In Group B, only miR-496 was up-regulated and 12 microRNAs, including the let-7 family, miR-1224, miR-125a-3p, miR-214, miR-22, miR-320, miR-708, and miR-93, were down-regulated. Bioinformatics analysis reveals that some of these microRNAs (miR-22, miR-214, miR-125a-3p, miR-320 and let-7 family) are associated with reduction of apoptosis. Here, we summarize the roles of key microRNAs associated with IGF-1 in the differentiation of BMSCs into NPCs. These findings may provide clues to further our understanding of the mechanisms and roles of microRNAs as key regulators of BMSC-derived NPC maintenance. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) - ReferenceElliott G et al. (DEC 2015) Nature Communications 6 1 6363
Intermediate DNA methylation is a conserved signature of genome regulation
The role of intermediate methylation states in DNA is unclear. Here, to comprehensively identify regions of intermediate methylation and their quantitative relationship with gene activity, we apply integrative and comparative epigenomics to 25 human primary cell and tissue samples. We report 18,452 intermediate methylation regions located near 36% of genes and enriched at enhancers, exons and DNase I hypersensitivity sites. Intermediate methylation regions average 57% methylation, are predominantly allele-independent and are conserved across individuals and between mouse and human, suggesting a conserved function. These regions have an intermediate level of active chromatin marks and their associated genes have intermediate transcriptional activity. Exonic intermediate methylation correlates with exon inclusion at a level between that of fully methylated and unmethylated exons, highlighting gene context-dependent functions. We conclude that intermediate DNA methylation is a conserved signature of gene regulation and exon usage. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) 07923 Dispase (1 U/mL) 07910 Trypsin-EDTA (0.05%) 19157 EasySep™ Human Memory CD4+ T Cell Enrichment Kit 36254 DMEM/F-12 with 15 mM HEPES 21000 RoboSep™-S 85850 mTeSR™1 07900 DNase I Solution (1 mg/mL) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 07923 Product Name: Dispase (1 U/mL) Catalog #: 07910 Product Name: Trypsin-EDTA (0.05%) Catalog #: 19157 Product Name: EasySep™ Human Memory CD4+ T Cell Enrichment Kit Catalog #: 36254 Product Name: DMEM/F-12 with 15 mM HEPES Catalog #: 21000 Product Name: RoboSep™-S Catalog #: 85850 Product Name: mTeSR™1 Catalog #: 07900 Product Name: DNase I Solution (1 mg/mL) - ReferenceNie S et al. (FEB 2015) Journal of proteome research 14 2 814--22
Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor, with dismal survival outcomes. Recently, cancer stem cells (CSCs) have been demonstrated to play a role in therapeutic resistance and are considered to be the most likely cause of cancer relapse. The identification of CSCs is an important step toward finding new and effective ways to treat GBM. Tenascin-C (TNC) protein has been identified as a potential marker for CSCs in gliomas based on previous work. Here, we have investigated the expression of TNC in tissue microarrays including 17 GBMs, 18 WHO grade III astrocytomas, 15 WHO grade II astrocytomas, 4 WHO grade I astrocytomas, and 7 normal brain tissue samples by immunohistochemical staining. TNC expression was found to be highly associated with the grade of astrocytoma. It has a high expression level in most of the grade III astrocytomas and GBMs analyzed and a very low expression in most grade II astrocytomas, whereas it is undetectable in grade I astrocytomas and normal brain tissues. Double-immunofluorescence staining for TNC and CD133 in GBM tissues revealed that there was a high overlap between theses two positive populations. The results were further confirmed by flow cytometry analysis of TNC and CD133 in GBM-derived stem-like neurospheres in vitro. A limiting dilution assay demonstrated that the sphere formation ability of CD133(+)/TNC(+) and CD133(-)/TNC(+) cell populations is much higher than that of the CD133(+)/TNC(-) and CD133(-)/TNC(-) populations. These results suggest that TNC is not only a potential prognostic marker for GBM but also a potential marker for glioma CSCs, where the TNC(+) population is identified as a CSC population overlapping with part of the CD133(-) cell population. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) 05752 NeuroCult™ NS-A Differentiation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05752 Product Name: NeuroCult™ NS-A Differentiation Kit (Human) - ReferenceYost SE et al. (FEB 2013) PLoS ONE 8 2 e56185
High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models
Recent advances in the ability to efficiently characterize tumor genomes is enabling targeted drug development, which requires rigorous biomarker-based patient selection to increase effectiveness. Consequently, representative DNA biomarkers become equally important in pre-clinical studies. However, it is still unclear how well these markers are maintained between the primary tumor and the patient-derived tumor models. Here, we report the comprehensive identification of somatic coding mutations and copy number aberrations in four glioblastoma (GBM) primary tumors and their matched pre-clinical models: serum-free neurospheres, adherent cell cultures, and mouse xenografts. We developed innovative methods to improve the data quality and allow a strict comparison of matched tumor samples. Our analysis identifies known GBM mutations altering PTEN and TP53 genes, and new actionable mutations such as the loss of PIK3R1, and reveals clear patient-to-patient differences. In contrast, for each patient, we do not observe any significant remodeling of the mutational profile between primary to model tumors and the few discrepancies can be attributed to stochastic errors or differences in sample purity. Similarly, we observe 96% primary-to-model concordance in copy number calls in the high-cellularity samples. In contrast to previous reports based on gene expression profiles, we do not observe significant differences at the DNA level between in vitro compared to in vivo models. This study suggests, at a remarkable resolution, the genome-wide conservation of a patient's tumor genetics in various pre-clinical models, and therefore supports their use for the development and testing of personalized targeted therapies. View PublicationCatalog #: Product Name: 05750 NeuroCult™ NS-A Basal Medium (Human) 05751 NeuroCult™ NS-A Proliferation Kit (Human) Catalog #: 05750 Product Name: NeuroCult™ NS-A Basal Medium (Human) Catalog #: 05751 Product Name: NeuroCult™ NS-A Proliferation Kit (Human)
Products 1 to 12 of 25 total
Shop By
Filter Results
- Resource Type
- Product Information Sheet 1 item
- Reference 112 items
- Safety Data Sheet 1 item
- Technical Manual 1 item
- Product Type
- Cell Culture Media and Supplements 1 item
- Area of Interest
- Angiogenic Cell Research 1 item
- Cancer 20 items
- Drug Discovery and Toxicity Testing 1 item
- Neuroscience 99 items
- Stem Cell Biology 2 items
- Brand
- ALDEFLUOR 1 item
- IntestiCult 1 item
- NeuroCult 110 items
- TeSR 1 item
- Cell Type
- Brain Tumor Stem Cells 65 items
- Cancer Cells and Cell Lines 14 items
- Neural Stem and Progenitor Cells 82 items
- Pluripotent Stem Cells 1 item